Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Medtronic
Argus Health
Julphar
Chubb
Colorcon
Cerilliant
Queensland Health
UBS

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XELJANZ XR

« Back to Dashboard

Clinical Trials for Xeljanz Xr

Trial ID Title Status Sponsor Phase Summary
NCT01932372 Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis Active, not recruiting Pfizer N/A The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice. 1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2) Long-term safety (particularly, malignant tumors and serious infections) and efficacy Occurrences of malignant tumors and serious infections will be compared with a control group.
NCT02157012 Evaluation of the Condition of Rheumatoid Arthritis After Treatment Recruiting Showa Inan General Hospital Phase 4 To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients
NCT02157012 Evaluation of the Condition of Rheumatoid Arthritis After Treatment Recruiting Shinshu University Phase 4 To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients
NCT02299297 An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Active, not recruiting Locks of Love Phase 2 This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment. There will be the option of increasing the treatment duration up to an additional 6 months beyond the initially scheduled 6 months of treatment, if clinically indicated, and at the discretion of the investigator.
NCT02299297 An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Active, not recruiting Julian M. Mackay-Wiggan Phase 2 This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment. There will be the option of increasing the treatment duration up to an additional 6 months beyond the initially scheduled 6 months of treatment, if clinically indicated, and at the discretion of the investigator.
NCT02996500 Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate Recruiting Pfizer Phase 2 This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at Week 12 in subjects with moderate-severe, active, RA who have had an inadequate response to MTX. PF-06650833 or matching placebo tablets will be administered orally QD under fasting conditions, and tofacitinib or matching tofacitinib placebo tablets will be administered orally BID for 12 weeks in a blinded fashion.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Xeljanz Xr

Condition Name

Condition Name for Xeljanz Xr
Intervention Trials
Rheumatoid Arthritis 3
Systemic Sclerosis 1
Scleroderma 1
Arthritis Juvenile Idiopathic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Xeljanz Xr
Intervention Trials
Arthritis 4
Arthritis, Rheumatoid 3
Scleroderma, Diffuse 1
Arthritis, Juvenile 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Xeljanz Xr

Trials by Country

Trials by Country for Xeljanz Xr
Location Trials
United States 5
Japan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Xeljanz Xr
Location Trials
Pennsylvania 2
Texas 1
Florida 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Xeljanz Xr

Clinical Trial Phase

Clinical Trial Phase for Xeljanz Xr
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Xeljanz Xr
Clinical Trial Phase Trials
Active, not recruiting 2
Not yet recruiting 2
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Xeljanz Xr

Sponsor Name

Sponsor Name for Xeljanz Xr
Sponsor Trials
Pfizer 4
University of Michigan 1
Julian M. Mackay-Wiggan 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Xeljanz Xr
Sponsor Trials
Other 5
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Moodys
AstraZeneca
Boehringer Ingelheim
Dow
Merck
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.